Dr Craig Rayner

CEO – d3 Medicine "Creative thinking must not be restricted by complexity and dogma"

Cross sector collaboration yields FDA approval for Tamiflu in infants

Leave a comment

http://news.yahoo.com/fda-approves-roches-tamiflu-infants-flu-symptoms-190834755–finance.html

An exciting day.

Today the FDA approved Tamiflu as the first anti-viral that may be used to treat influenza in children under the age of one year.

According to the CDC, infants are especially vulnerable to developing complications from influenza and those 6 months of age and younger have the highest rates of hospitalization.

Conducting clinical trials in such vulnerable patients is extremely complex, yielding low patient numbers, and requires novel approaches in order to identify dosing recommendations.

In this case, it was through the longstanding (since 2006) successful collaboration between NIH Collaborative Antiviral Study Group (CASG) and Roche. Each group conducted  dedicated clinical studies, yielding a total of 135 children under 1 year old with confirmed cases of the flu. These investigations provided safety information for Tamiflu in infants, and innovative clinical pharmacology strategies were applied to assist with defining dose recommendations.

 

Advertisements

Author: Dr Craig Rayner

CEO of d3 Medicine LLC and Adjunct Associate Professor in Faculty of Pharmacy & Pharmaceutical Sciences at Monash University. Views are my own and not necessarily reflective of d3 Medicine or Monash University.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s